These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18957051)

  • 1. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
    Scarr E; Dean B
    J Neurochem; 2008 Dec; 107(5):1188-95. PubMed ID: 18957051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a muscarinic hypothesis of schizophrenia.
    Raedler TJ; Bymaster FP; Tandon R; Copolov D; Dean B
    Mol Psychiatry; 2007 Mar; 12(3):232-46. PubMed ID: 17146471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the cholinergic system in the pathology and treatment of schizophrenia.
    Scarr E; Dean B
    Expert Rev Neurother; 2009 Jan; 9(1):73-86. PubMed ID: 19102670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscarinic mechanisms in psychotic disorders.
    McKinzie DL; Bymaster FP
    Handb Exp Pharmacol; 2012; (213):233-65. PubMed ID: 23027418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia.
    Dean B; Crook JM; Opeskin K; Hill C; Keks N; Copolov DL
    Mol Psychiatry; 1996 Mar; 1(1):54-8. PubMed ID: 9118315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration.
    McOmish CE; Burrows E; Howard M; Scarr E; Kim D; Shin HS; Dean B; van den Buuse M; Hannan AJ
    Mol Psychiatry; 2008 Jul; 13(7):661-72. PubMed ID: 17667964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia.
    Maehara S; Hikichi H; Satow A; Okuda S; Ohta H
    Pharmacol Biochem Behav; 2008 Nov; 91(1):140-9. PubMed ID: 18651995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscarinic receptors in psychiatric disorders - can we mimic 'health'?
    Scarr E
    Neurosignals; 2009; 17(4):298-310. PubMed ID: 19816066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome.
    Barak S
    Behav Brain Res; 2009 Dec; 204(2):335-51. PubMed ID: 19376161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics in the early stage of development.
    Biedermann F; Fleischhacker WW
    Curr Opin Psychiatry; 2009 May; 22(3):326-30. PubMed ID: 19346948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review.
    Inta D; Monyer H; Sprengel R; Meyer-Lindenberg A; Gass P
    Neurosci Biobehav Rev; 2010 Mar; 34(3):285-94. PubMed ID: 19651155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are cannabinoid receptor knockout mice animal models for schizophrenia?
    Fritzsche M
    Med Hypotheses; 2001 Jun; 56(6):638-43. PubMed ID: 11399112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia.
    Deng C; Huang XF
    J Neurosci Res; 2005 Sep; 81(6):883-90. PubMed ID: 16041805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.
    Weiner I; Arad M
    Behav Brain Res; 2009 Dec; 204(2):369-86. PubMed ID: 19433114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.